sharetrader
Page 1134 of 1162 FirstFirst ... 1346341034108411241130113111321133113411351136113711381144 ... LastLast
Results 16,996 to 17,010 of 17419
  1. #16996
    Member
    Join Date
    Mar 2014
    Posts
    346

    Default

    Quote Originally Posted by blackcap View Post
    How does getting money for 17k tests make them cashflow positive? lets say $500 per test by my calcs that is $8,500,000. So would still be operating at a loss.
    Reimbursement rate is circa 1040 NZD per test, current market in only three countries is 15697 tests = $16,000,000 sales. chuck in some overdue reimbursement and the sentiment could be very different. Yes reimbursement rates are different in different countries. I am talking very roughly and with a glass half full.


    Total laboratory throughput (which includes commercial sales as well as
    tests from User Programmes) grew to 15,697 tests in FY19, a 9% increase on
    FY18.


  2. #16997
    Member
    Join Date
    Jul 2015
    Posts
    372

    Default

    Quote Originally Posted by Carpenterjoe View Post
    Wow, do you think FDA approval would be any easier?

    Look at CUV, I think its been circa 10 years and two different brand names and they are now just getting FDA approval, Hopefully anyway. Otherwise the 400% i am up will get smashed.


    The goal posts are always changing,

    https://www.fda.gov/medical-devices/...eveloped-tests


    The good news is, PEB are one announcement away from being cashflow positive.
    The easy short term choice is rarely the best long term one.

    Look at what the real players do to make $
    https://diagnostics.roche.com/global...tion-test.html

    Lots of bankrupted companies were "one announcement away from being cashflow positive"

  3. #16998
    Legend Balance's Avatar
    Join Date
    Feb 2003
    Posts
    10,276

    Default

    Quote Originally Posted by kiwidollabill View Post
    The easy short term choice is rarely the best long term one.

    Look at what the real players do to make $
    https://diagnostics.roche.com/global...tion-test.html

    Lots of bankrupted companies were "one announcement away from being cashflow positive"
    This is where one has to grudgingly acknowledge the ability of DD & PEB to spin out the story from one capital raising to another.

  4. #16999
    Member
    Join Date
    Mar 2014
    Posts
    346

    Default

    Quote Originally Posted by kiwidollabill View Post
    The easy short term choice is rarely the best long term one.

    Look at what the real players do to make $
    https://diagnostics.roche.com/global...tion-test.html

    Lots of bankrupted companies were "one announcement away from being cashflow positive"
    Thanks will do,

    Seems it relies on a Cobas amplification system and the system is rather large and at 50k+ a machine,

    Out of interest do you need an invasive tumor sample to run the test?

    Do you know how long is took Roche to research and gain approval for both technologies?

    At first glance this is a targeted system that is used to decide what drugs to use to save someone from metastatic colorectal cancer, it is not a front line diagnostic test

    At first glace this seems like comparing an apple with a brick.
    This example is why the likes of PEB and MDX need to succeed.

    Yes the big players have deep pockets are able to force decision making at all levels.

    Happy Fridays

  5. #17000
    Member
    Join Date
    Jul 2015
    Posts
    372

    Default

    Quote Originally Posted by Carpenterjoe View Post
    Thanks will do,

    Seems it relies on a Cobas amplification system and the system is rather large and at 50k+ a machine,

    Out of interest do you need an invasive tumor sample to run the test?

    Do you know how long is took Roche to research and gain approval for both technologies?

    At first glance this is a targeted system that is used to decide what drugs to use to save someone from metastatic colorectal cancer, it is not a front line diagnostic test

    At first glace this seems like comparing an apple with a brick.
    This example is why the likes of PEB and MDX need to succeed.

    Yes the big players have deep pockets are able to force decision making at all levels.

    Happy Fridays
    Do you realise that CXbladder is run on Roche Lightcyclers which are basically the non-FDA version of the Cobas.....????

    I'll just leave the rest, its best not to make assessments on 'at first glance....'

  6. #17001
    Member
    Join Date
    Mar 2014
    Posts
    346

    Default

    Quote Originally Posted by kiwidollabill View Post
    Do you realise that CXbladder is run on Roche Lightcyclers which are basically the non-FDA version of the Cobas.....????

    I'll just leave the rest, its best not to make assessments on 'at first glance....'
    Ok then, Thanks tho, i didn't.

    Ill leave this discussion alone,

  7. #17002
    Legend Balance's Avatar
    Join Date
    Feb 2003
    Posts
    10,276

    Default

    Check this out :

    Director, Market Access and Reimbursement
    Pacific Edge Diagnostics USA Ltd.
    Hershey, PA

    Responsible for the development and implementation of all market access strategies to secure and maintain access, coverage and reimbursement for all Pacific Edge Diagnostics products within the U.S.

    • Developed and implemented all payer coverage strategies for Medicare, and Commercial payers which resulted in positive reimbursement for CxBladder.
    • Collaborated with CMS to ensure appropriate implementation of access and pricing strategy regarding the new CMS proposed rule.
    • Developed and submitted Federal Supply Schedule packet to secure access to CxBladder in VA/DOD as well as appropriate government pricing.
    • Created and implemented field reimbursement strategies to support providers and internal stakeholders by removing reimbursement barriers and creating access to CxBladder.
    • Collaborated with a cross-functional team of marketing, sales and medical affairs leaders to develop and implement tools to support commercial payers, Medicare, Medicaid and CMS, reimbursement initiatives.
    • Effectively solicited, cultivated and established Key Opinion Leaders and CAC members, both regionally and nationally to support payer and reimbursement initiatives.
    • Responsible for the over sight and implementation of pricing and contracting strategy for all key customer segments which resulted in increase access and reimbursement for CxBladder
.
    • Developed clinical payer scientific dossier to support coverage of CxBladder.
    • Successfully developed and submitted to Medicare MAC the clinical value proposition, validation, and utility dossier for LCD reconsideration coverage inclusion of CxBladder.
    • Developed and Implemented the Pacific Edge Patient Financial Assistance Program to ensure financial access to Cxbladder



  8. #17003
    Member
    Join Date
    Aug 2017
    Posts
    56

    Default

    Quote Originally Posted by blackcap View Post
    How does getting money for 17k tests make them cashflow positive? lets say $500 per test by my calcs that is $8,500,000. So would still be operating at a loss.
    The reimbursement rate was agreed last October at USD$760 per test

  9. #17004
    Member
    Join Date
    Aug 2017
    Posts
    56

    Default

    Quote Originally Posted by Balance View Post
    Check this out :

    Director, Market Access and Reimbursement
    Pacific Edge Diagnostics USA Ltd.
    Hershey, PA

    Responsible for the development and implementation of all market access strategies to secure and maintain access, coverage and reimbursement for all Pacific Edge Diagnostics products within the U.S.

    • Developed and implemented all payer coverage strategies for Medicare, and Commercial payers which resulted in positive reimbursement for CxBladder.
    • Collaborated with CMS to ensure appropriate implementation of access and pricing strategy regarding the new CMS proposed rule.
    • Developed and submitted Federal Supply Schedule packet to secure access to CxBladder in VA/DOD as well as appropriate government pricing.
    • Created and implemented field reimbursement strategies to support providers and internal stakeholders by removing reimbursement barriers and creating access to CxBladder.
    • Collaborated with a cross-functional team of marketing, sales and medical affairs leaders to develop and implement tools to support commercial payers, Medicare, Medicaid and CMS, reimbursement initiatives.
    • Effectively solicited, cultivated and established Key Opinion Leaders and CAC members, both regionally and nationally to support payer and reimbursement initiatives.
    • Responsible for the over sight and implementation of pricing and contracting strategy for all key customer segments which resulted in increase access and reimbursement for CxBladder
.
    • Developed clinical payer scientific dossier to support coverage of CxBladder.
    • Successfully developed and submitted to Medicare MAC the clinical value proposition, validation, and utility dossier for LCD reconsideration coverage inclusion of CxBladder.
    • Developed and Implemented the Pacific Edge Patient Financial Assistance Program to ensure financial access to Cxbladder



    He left the job 4 years ago

  10. #17005
    Legend Balance's Avatar
    Join Date
    Feb 2003
    Posts
    10,276

    Default

    Quote Originally Posted by Nigelk View Post
    He left the job 4 years ago
    Precisely!

    Note the "Successfully developed and submitted to Medicare MAC the clinical value proposition, validation, and utility dossier for LCD reconsideration coverage inclusion of CxBladder."

    Looks to me like PEB was rejected for LCD consideration 5 years ago! Was never mentioned once by DD or the company - it was all rah rah rah go go go, remember?
    Last edited by Balance; 21-06-2019 at 05:38 PM.

  11. #17006
    AWOL
    Join Date
    Sep 2012
    Location
    Vacation
    Posts
    2,414

    Default

    "Iterative" was the key word from past company advice.

  12. #17007
    Legend Balance's Avatar
    Join Date
    Feb 2003
    Posts
    10,276

    Default

    Quote Originally Posted by Minerbarejet View Post
    "Iterative" was the key word from past company advice.
    Yup - that's PEB, same repetitive story just as this NBR headline :

    https://www.nbr.co.nz/analysis/pacif...ss-or-oblivion

  13. #17008
    Member Drew95's Avatar
    Join Date
    Mar 2019
    Location
    Auckland
    Posts
    38

    Default

    Clinical study supports adoption of Cxbladder

    24/6/2019, 12:26 pmGENERALCLINICAL STUDY SUPPORTS ADOPTION OF CXBLADDER INTO NEW CLINCAL PATHWAY
    Canterbury DHB publishes real-world clinical study with cementing evidence supporting the adoption of Cxbladder into the new clinical pathway


    https://www.nzx.com/announcements/336487

  14. #17009
    Senior Member
    Join Date
    Jul 2015
    Location
    Napier
    Posts
    971

    Default

    Quote Originally Posted by Drew95 View Post
    Clinical study supports adoption of Cxbladder

    24/6/2019, 12:26 pmGENERALCLINICAL STUDY SUPPORTS ADOPTION OF CXBLADDER INTO NEW CLINCAL PATHWAY
    Canterbury DHB publishes real-world clinical study with cementing evidence supporting the adoption of Cxbladder into the new clinical pathway


    https://www.nzx.com/announcements/336487
    Great show me money and please donít ask for anymore the dilution is killing shareholders wealth

  15. #17010
    AWOL
    Join Date
    Sep 2012
    Location
    Vacation
    Posts
    2,414

    Default

    Quote Originally Posted by Balance View Post
    Yup - that's PEB, same repetitive story just as this NBR headline :

    https://www.nbr.co.nz/analysis/pacif...ss-or-oblivion

    Why do you think they called it Pacific Edge?

Tags for this Thread

Bookmarks

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •